Massachusetts Financial Services
BCRX icon

Massachusetts Financial Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Massachusetts Financial Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-131,711
Closed -$1,000K – 921
2025
Q3 		$1,000K Buy
131,711
+8,663
+7% +$72.1K ﹤0.01% 803
2025
Q2 		$1.1M Buy
+123,048
New +$1.15M ﹤0.01% 803

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Massachusetts Financial Services's BCRX Position: Q4 2025 in Review

Massachusetts Financial Services sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 131,711 shares — an estimated $1,000K sold.

Massachusetts Financial Services first reported a position in BCRX in Q2 2025 and held it in 2 quarters. The position peaked at $1.1M in Q2 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Massachusetts Financial Services reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Massachusetts Financial Services sold 131,711 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $1,000K.
  • Massachusetts Financial Services first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Massachusetts Financial Services's BioCryst Pharmaceuticals position peaked at $1.1M in Q2 2025.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Massachusetts Financial Services's 13F filing for Q4 2025, filed 22 Jan 2026.